Mallinckrodt announces the appointment of Lisa French as Chief Commercial Officer | PR Newswire

DUBLIN, September 19, 2022 /PRNewswire/ — Mallinckrodt plc (OTCMKTS: MNKPF) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today announced its appointment Lisa French as Executive Vice President and Chief Commercial Officer October 1, 2022. Ms. French has more than 30 years of commercial biopharmaceutical experience and will oversee the development and implementation Mallinckrodt commercialization strategy. Ms. French will serve on the Executive Committee and succeed Hugh O’Neillwho left Mallinckrodt as of September 16, 2022.

Ms. French most recently created and led the US Women’s Health commercial group for Organon & Co. after its separation from Merck. She previously held multiple leadership positions at Merck, where she ultimately led all aspects of the multibillion-dollar brand, led commercial innovation initiatives and oversaw multiple sales teams.

Sigi Olafssonpresident and chief executive officersaid: “I am delighted to welcome Lisa Mallinckrodt as our new Chief Commercial Officer and as a member of our Executive Committee. Lisa has decades of commercialization experience with deep expertise and a proven track record of developing and implementing effective and growth-driven commercialization strategies. I’m sure her insight and experience will be invaluable as we continue to work on developing our signature pipeline, Mallinckrodt existing products to new markets and territories and stabilize our portfolio – all for the benefit of our patients, shareholders and other stakeholders.”

Ms French said: “One of the reasons I was attracted Mallinckrodt is the company’s focus on innovative drug development and commercialization for patients with severe and critically underserved conditions. The company’s portfolio consists of core products with a good reputation and strong brand recognition. I look forward to working closely with Siggi and Mallinckrodt team to build on that strong foundation.”

About Lisa French

Ms. French is a biopharmaceutical commercial executive with over 30 years of experience in US market entry commercialization strategy development and experience throughout the therapeutic lifecycle. Most recently, she served as U.S. Business Unit Manager for women’s health franchise Organon & Co., where she led the commercial team. Ms. French previously held positions of responsibility at Merck, where she served as Associate Vice President of US Marketing – HPV Franchise; US Vice President of Business Model Strategy and Innovation; Executive Director of US Federal Policy; National Executive Director of Commercial Operations – Women’s Health; National Director of Commercial Operations – HIV; Regional Director of Commercial Operations – Chronic Care; and Regional Director of Commercial Operations – Cardiovascular Care, among other roles.

Ms. French holds a bachelor’s degree in biology West Chester University and completed Harvard Business School New leaders and Leadership and strategy executive programs.

About Mallinckrodt

Mallinckrodt is a global business comprised of several wholly-owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands segment focuses include autoimmune and rare diseases in specialty areas such as neurology, rheumatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory resuscitation; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generics and active pharmaceutical ingredients. To learn more about Mallinckrodtvisiting

Mallinckrodt uses its website as a channel to disseminate important company information such as press releases, investor presentations and other financial information. It also uses its website to facilitate public access to timely information about the Company before or in lieu of a press release or filing with the US Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look for important and time-critical information on the website’s Investor Relations page. Website visitors may also register to receive automatic e-mail and other notifications of new information on the Investor Relations website page.


Statements in this release that are not purely historical, including statements regarding Mallinckrodt’s future financial condition and results of operations, legal, economic, business, competitive and/or regulatory factors affecting Mallinckrodt’s business, and any other statements regarding events or events that Mallinckrodt anticipates or anticipates will or may occur in the future may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or implied in such forward-looking statements, and you should not place undue reliance on any such forward-looking statements. The Risk Factors section of Mallinckrodt’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 has been updated Mallinckrodt Quarterly Report on Form 10-Q for the quarter ended July 1, 2022 and other filings with the SEC identify and further describe the risks and uncertainties to which Mallinckrodt’s business is exposed. Forward-looking statements made herein speak only as of the date hereof, and Mallinckrodt undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events or developments or otherwise, except as required by law.


Investor Relations

Daniel Speciale

Global Corporate Controller and Chief Investor Relations Officer


Derek Belz

Vice President of Investor Relations


mass media

Michael Freitag / Aaron Palash / Aura Reinhardt

Joel FrankWilkinson Brimmer Katcher


Mallinckrodt, the “M” mark, and the Mallinckrodt Pharmaceuticals logo are trademarks of the Mallinckrodt Company. Other brands are trademarks of Mallinckrodt or their respective owners. ©September 22, 2022

Browse original content to download media:

THE SOURCE Mallinckrodt plc

Source link